Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,924.06 ($23.49) and traded as high as GBX 2,064 ($25.20). Hikma Pharmaceuticals shares last traded at GBX 2,062 ($25.18), with a volume of 345,386 shares.
Hikma Pharmaceuticals Trading Down 1.7 %
The firm has a fifty day moving average of GBX 1,927.95 and a two-hundred day moving average of GBX 1,924.78. The company has a market cap of £4.50 billion, a PE ratio of 3,116.92, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.48.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.
Read More
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
